HPV prophylactic vaccination: The first years and what to expect from now (Q37824520)

23 August 2017

1 reference

title

HPV prophylactic vaccination: The first years and what to expect from now (English)

1 reference

Crossref

https://api.crossref.org/works/10.1016/J.CANLET.2010.12.002

21 November 2024

Luisa Lina Villa

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A21190794

21 November 2024

language of work or name

English

0 references

publication date

28 December 2010

1 reference

full work available at URL

23 August 2017

https://api.elsevier.com/content/article/PII:S0304383510005525?httpAccept=text/xml

1 reference

Crossref

https://api.crossref.org/works/10.1016/J.CANLET.2010.12.002

https://api.elsevier.com/content/article/PII:S0304383510005525?httpAccept=text/plain

21 November 2024

1 reference

Crossref

https://api.crossref.org/works/10.1016/J.CANLET.2010.12.002

21 November 2024

1 reference

23 August 2017

volume

305

1 reference

23 August 2017

1 reference

23 August 2017

page(s)

106-112

1 reference

Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis

23 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.12.002

Epidemiology of human papillomavirus infection in men, cancers other than cervical and benign conditions

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.12.002

Overview of recurrent respiratory papillomatosis

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.12.002

Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.12.002

Human papillomavirus infection and time to progression and regression of cervical intraepithelial neoplasia

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.12.002

Case-control study of human papillomavirus and oropharyngeal cancer

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.12.002

The human papillomavirus infection in men study: human papillomavirus prevalence and type distribution among men residing in Brazil, Mexico, and the United States.

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.12.002

Overview of the clinical development and results of a quadrivalent HPV (types 6, 11, 16, 18) vaccine

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.12.002

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.12.002

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.12.002

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.12.002

Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.12.002

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.12.002

Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.12.002

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.12.002

Effect of human papillomavirus 16/18 L1 viruslike particle vaccine among young women with preexisting infection: a randomized trial

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.12.002

Human papillomavirus vaccines and the potential for cross-protection between related HPV types

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.12.002

Efficacy, duration of immunity and cross protection after HPV vaccination: a review of the evidence

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.12.002

Quadrivalent human papillomavirus vaccine

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.12.002

Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.12.002

Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.12.002

Immune response to human papillomavirus after prophylactic vaccination with AS04-adjuvanted HPV-16/18 vaccine: improving upon nature

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.12.002

Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.12.002

High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.12.002

Chapter 28: Studies to assess the long-term efficacy and effectiveness of HPV vaccination in developed and developing countries

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.12.002

Safety and persistent immunogenicity of a quadrivalent human papillomavirus types 6, 11, 16, 18 L1 virus-like particle vaccine in preadolescents and adolescents: a randomized controlled trial.

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.12.002

Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.12.002

Safety, immunogenicity, and efficacy of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine in women aged 24-45 years: a randomised, double-blind trial

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.12.002

HPV vaccination against cervical cancer in women above 25 years of age: key considerations and current perspectives

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.12.002

Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.12.002

Progress in the research on HPV vaccination: updates from the 25th International Papillomavirus Conference in Malmo, Sweden, 2009

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.12.002

Rapid decline in presentations of genital warts after the implementation of a national quadrivalent human papillomavirus vaccination programme for young women.

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.12.002

Monitoring HPV vaccination

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.12.002

Translational mini-review series on vaccines: Monitoring of human papillomavirus vaccination

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.12.002

Results of the first WHO international collaborative study on the standardization of the detection of antibodies to human papillomaviruses.

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.12.002

Chapter 20: Issues in planning cervical cancer screening in the era of HPV vaccination

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.12.002

Chapter 16: HPV vaccines in immunocompromised women and men.

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.12.002

WHO position on HPV vaccines

21 November 2024

1 reference

https://api.crossref.org/works/10.1016/J.CANLET.2010.12.002

21 November 2024

Identifiers

1 reference

23 August 2017

1 reference